Effects of Diabetes mellitus, obesity and sedentary lifestyle in Alzheimer's dementia - Interaction of insulin and amyloid and phosphorylated tau-protein;Einfluss von Diabetes mellitus, übergewicht und bewegungsmangel auf morbus Alzheimer: Interaktion von insulin mit amyloid und phosphoryliertem tau-protein

Klinikarzt

Volumn 38, Issue 5, 2009, Pages 228-233

  Kopf, Daniel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alzheimer's disease; Diabetes mellitus; Obesity; Prevention

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; GLUCOCORTICOID; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLYCOGEN SYNTHASE KINASE 3; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN CORTEX; BRAIN FUNCTION; BRAIN METABOLISM; COGNITION; CORPUS STRIATUM; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; LIFESTYLE MODIFICATION; MEMORY CONSOLIDATION; MOLECULAR INTERACTION; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE GROWTH; NEUROFIBRILLARY TANGLE; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PRIMARY PREVENTION; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SECONDARY PREVENTION; SENILE PLAQUE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WEIGHT CONTROL;

EID: 68849124100     PISSN: 03412350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1225545     Document Type: Review

References (33)

1. Bucht G, Adolfsson R, Lithner F, Winblad B. Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 1983; 213: 387-392
2. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998; 105: 415-422 (Pubitemid 28365026)
3. Kopf D, Frölich L. Risk of incident Alzheimer's disease in diabetic patients: A systematic review of prospective trials. J Alzh Dis 2009; im Druck
4. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007; 56: 211-216 (Pubitemid 46263130)
5. Rönnemaa E, Zethelius B, Sundelöf J et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008; 71: 1065-1071
6. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-1192 (Pubitemid 39350015)
7. Bergmann C, Sano M. Cardiac risk factors and potential treatments in Alzheimer's disease. Neurol Res 2006; 28: 595-604 (Pubitemid 44433318)
8. Whitmer RA. The epidemiology of adiposity and dementia. Curr Alzheimer Res 2007; 4: 117-122
9. Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565-1572
10. Peters A, Schweiger U, Pellerin L et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004; 28: 143-180 (Pubitemid 38692362)
11. McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004; 490: 13-24
12. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 2000; 24: 855-872
13. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004; 490: 5-12
14. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004; 490: 71-81 (Pubitemid 38482161)
15. Paulus K, Schulz C, Lehnert H. Central nervous effects of leptin and insulin on hippocampal leptin and insulin receptor expression following a learning task in Wistar rats. Neuropsychobiology 2005; 51: 100-106 (Pubitemid 40522802)
16. Benedict C, Hallschmid M, Hatke A et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-1334 (Pubitemid 39024358)
17. Needham BE, Wlodek ME, Ciccotosto GD et al. Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J Pathol 2008; 215: 155-163
18. Grimm MO, Grimm HS, Tomic I et al. Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. J Biol Chem 2008; 283: 11302-11311
19. De Felice FG, Vieira MN, Bomfim TR et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009; 106: 1971-1976
20. Frölich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 290-293 (Pubitemid 30038089)
21. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27: 190-198
22. Elliott E, Ginzburg I. The role of neurotrophins and insulin on tau pathology in Alzheimer's disease. Rev Neurosci 2006; 17: 635-642 (Pubitemid 46144733)
23. Rovio S, Kåreholt I, Helkala EL et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 2005; 4: 705-711 (Pubitemid 41457285)
24. Lautenschlager NT, Cox KL, Flicker L et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008; 300: 1027-1037
25. Yaffe K, Blackwell T, Whitmer RA et al. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 2006; 10: 293-295 (Pubitemid 44351825)
26. Beeri MS, Schmeidler J, Silverman JM et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008; 71: 750-757
27. Watson GS, Cholerton BA, Reger MA et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-958
28. Hanyu H, Sato T, Kiuchi A et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009; 57: 177-179
29. Risner ME, Saunders AM, Altman JF et al. Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246-254
30. Leibson CL, Rocca WA, Hanson VA et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301-308 (Pubitemid 27082028)
31. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14: 77-83
32. Ott A, Stolk RP, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942
33. Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-1262